While Myriad Genetics, Inc has overperformed by 4.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -40.50%, with highs and lows ranging from $29.30 to $12.04, whereas the simple moving average fell by -38.99% in the last 200 days.
On February 12, 2025, Craig Hallum started tracking Myriad Genetics, Inc (NASDAQ: MYGN) recommending Buy. A report published by UBS on December 10, 2024, Initiated its previous ‘Neutral’ rating for MYGN. Leerink Partners also Downgraded MYGN shares as ‘Market Perform’, setting a target price of $21 on the company’s shares in a report dated December 09, 2024. Morgan Stanley Initiated an Equal-Weight rating on September 19, 2024, and assigned a price target of $32. Wells Fargo initiated its ‘Overweight’ rating for MYGN, as published in its report on August 28, 2024. Scotiabank’s report from June 27, 2024 suggests a price prediction of $29 for MYGN shares, giving the stock a ‘Sector Outperform’ rating. Jefferies also rated the stock as ‘Underperform’.
Analysis of Myriad Genetics, Inc (MYGN)
Further, the quarter-over-quarter increase in sales is 11.15%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Myriad Genetics, Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -16.39% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.73, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.03M can be a very valuable indicator of volatility for MYGN stock. On a monthly basis, the volatility of the stock is set at 5.40%, whereas on a weekly basis, it is put at 3.74%, with a gain of 1.24% over the past seven days. Furthermore, long-term investors anticipate a median target price of $19.18, showing growth from the present price of $13.09, which can serve as yet another indication of whether MYGN is worth investing in or should be passed over.
How Do You Analyze Myriad Genetics, Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.73%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 101.70% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
MYGN shares are owned by institutional investors to the tune of 101.70% at present.
